Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxford BioMedica has received approval by the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the Phase I/IIa clinical development of UshStat, to treat Usher syndrome type 1B.
Subscribe to our email newsletter
UshStat was developed using LentiVector platform technology, which is a gene delivery system, with applications in product development and discovery research.
The open label, dose escalation Phase I/IIa study will enrol around 18 patients with Usher syndrome type 1B at the Oregon Health and Science University’s Casey Eye Institute, Portland, Oregon.
The trial, which is likely to begin by the end of 2011, will assess three dose levels for safety, tolerability and aspects of biological activity.